Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy

Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared to CD3-targeted T-cell depletion

Transpl Infect Dis.

Triplett BM, Muller B, Kang G, Ying L, Cross SJ, Moen J, Cunningham L, Janssen W, Mamcarz E, Shook DR, Srinivasan A, Choi J, Hayden RT, Leung W

doi: 10.1111/tid.12823.

ImmunotherapyT Cells

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

J Autoimmun.

Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P

doi: 10.1016/j.jaut.2019.102310.

Immunotherapy

Reprogramming T-cells for adoptive immunotherapy of ovarian cancer

Expert Opin Biol Ther.

Genta S, Ghisoni E, Giannone G, Mittica G, Valabrega G

Immunotherapy

Obesity induced T cell dysfunction and implications for cancer immunotherapy

Curr Opin Immunol.

Aguilar EG, Murphy WJ

doi: 10.1016/j.coi.2018.03.012.

ImmunotherapyImmunomodulation

Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy

★ 3 Recommended by Alexander Meisel, Faculty Member

J Immunother Cancer

Rodrigues Mantuano N, Natoli M, Zippelius A, Läubli H

doi: 10.1136/jitc-2020-001222

Immunotherapy

Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy

Nat Commun.

Kallert SM, Darbre S, Bonilla WV, Kreutzfeldt M, Page N, Müller P, Kreuzaler M, Lu M, Favre S, Kreppel F, Löhning M, Luther SA, Zippelius A, Merkler D, Pinschewer DD

doi: 10.1038/ncomms15327.

ImmunotherapyT Cells

Cytometric analysis of T cell phenotype using cytokine profiling for improved manufacturing of an EBV-specific T cell therapy

Clin Exp Immunol

Cooper RS, Kowalczuk A, Wilkie G, Vickers MA, Turner ML, Campbell JDM, Fraser AR

doi: 10.1111/cei.13640

T Cells

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Semin Cancer Biol.

Kumar P, Saini S, Prabhakar BS

doi: 10.1016/j.semcancer.

T Cells

Engineering CAR-T Cells for Improved Function Against Solid Tumors

Front Immunol.

Morgan MA, Schambach A

doi: 10.3389/fimmu.2018.02493.

Related content

Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared to CD3-targeted T-cell depletion

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

Reprogramming T-cells for adoptive immunotherapy of ovarian cancer

Obesity induced T cell dysfunction and implications for cancer immunotherapy

Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy

Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy

Cytometric analysis of T cell phenotype using cytokine profiling for improved manufacturing of an EBV-specific T cell therapy

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Engineering CAR-T Cells for Improved Function Against Solid Tumors